Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, suggests new tools to help detect silent progression in multiple sclerosis (MS). There are clear limitations with the Expanded Disability Status Scale (EDSS) used to measure progression: it is not sensitive to change and is only measured every six months. Tools that could collect data every day would generate clinically meaningful measures that will allow monitoring silent progression in a more sensitive manner. Several studies have shown a correlation between the number of daily steps and EDSS score. This interview took place during the XXV World Congress of Neurology.
Dr Tintoré has received compensation for:
Consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Jansen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals.
Receipt grants and research supports from Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000. Biogen-Idec, Novartis.